Luminex Corporation Presents at UBS Global Healthcare Conference, May-21-2013 01:00 PM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Patrick J. Balthrop, Chief Executive Officer, President, Director, Member of Executive Committee and Member of Strategy & Development Committee.

Luminex Corporation announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, total revenue was $53,200,000 compared to $48,727,000 a year ago. Total operating loss was $1,552,000 compared to $5,608,000 a year ago. Loss before income taxes was $1,587,000 compared to income before income taxes of $5,606,000 a year ago. Net loss $2,511,000 or $0.06 diluted per share compared to net income of $3,527,000 or $0.08 diluted per share a year ago. Adjusted net income was $7,858,000 or $0.19 diluted per share compared to $6,606,000 or $0.15 diluted per share a year ago. Non-GAAP basis, the company generated net income of $7.7 million, or $0.19 per diluted share, up $0.04 or 27% from $0.15 per diluted share in the prior period. Net cash provided by operating activities was $10,019,000 against net cash used in operations of $29,000. Purchase of property and equipment was $2,791,000 against $1,596,000 a year ago. Acquired technology rights were $930,000. The company reaffirms its 2013 annual revenue guidance of between $220 million and $230 million. The company remains confident in ability to maintain gross margins in the 70% range for 2013.

Luminex Corporation received U.S. FDA clearance of its MAGPIX instrument, with its xTAG Gastrointestinal Pathogen Panel (xTAG GPP). This is the first clinical assay to be cleared on MAGPIX. xTAG GPP is the first U.S. IVD cleared test that can simultaneously detect 11 common viral, bacterial, and parasitic causes of infectious gastroenteritis from a single patient sample. Based on Luminex's xMAP(R) Technology, the easy-to-use MAGPIX instrument is a versatile multiplexing platform capable of performing qualitative and quantitative analysis of proteins and nucleic acids in a variety of sample matrices. MAGPIX is compact making it attractive to laboratories with limited bench space. This affordable system can perform up to 50 different tests in a single reaction volume, greatly reducing sample input, reagents, and labor while improving productivity. Traditional GI testing technologies and methods can take several days to deliver a single result depending on the pathogen. xTAG GPP is capable of delivering multiple results within five hours. Simultaneous molecular testing on a single sample within a single shift provides significant benefits to laboratories in terms of workflow and resource utilization.